Ultimovacs ASA (OL:ULTI) — Market Cap & Net Worth
Market Cap & Net Worth: Ultimovacs ASA (ULTI)
Ultimovacs ASA (OL:ULTI) has a market capitalization of $52.14 Million (Nkr495.45 Million) as of May 23, 2026. Listed on the OL stock exchange, this Norway-based company holds position #21811 globally and #196 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ultimovacs ASA's stock price Nkr14.40 by its total outstanding shares 34406100 (34.41 Million). Analyse Ultimovacs ASA (ULTI) cash conversion ratio to see how efficiently the company converts income to cash.
Ultimovacs ASA Market Cap History: 2019 to 2025
Ultimovacs ASA's market capitalization history from 2019 to 2025. Data shows change from $141.20 Million to $52.14 Million (-10.14% CAGR).
Ultimovacs ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ultimovacs ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ULTI by Market Capitalization
Companies near Ultimovacs ASA in the global market cap rankings as of May 23, 2026.
Key companies related to Ultimovacs ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.03 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #414 globally with a market cap of $66.20 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #577 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #598 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.03 Billion | $433.54 |
| #414 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.20 Billion | $642.59 |
| #577 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #598 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Ultimovacs ASA Historical Marketcap From 2019 to 2025
Between 2019 and today, Ultimovacs ASA's market cap moved from $141.20 Million to $ 52.14 Million, with a yearly change of -10.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Nkr52.14 Million | +518.03% |
| 2024 | Nkr8.44 Million | -98.10% |
| 2023 | Nkr444.60 Million | +11.64% |
| 2022 | Nkr398.26 Million | -2.48% |
| 2021 | Nkr408.39 Million | +41.00% |
| 2020 | Nkr289.64 Million | +105.13% |
| 2019 | Nkr141.20 Million | -- |
End of Day Market Cap According to Different Sources
On May 1st, 2026 the market cap of Ultimovacs ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.14 Million USD |
| MoneyControl | $52.14 Million USD |
| MarketWatch | $52.14 Million USD |
| marketcap.company | $52.14 Million USD |
| Reuters | $52.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.